F2 rs1799963 and Prothrombin Blood Clot Risk
- 5 days ago
- 6 min read
F2 rs1799963 is a well-established genetic variant associated with increased production of prothrombin, an important blood-clotting protein. The variant is commonly called prothrombin G20210A and can increase susceptibility to venous blood clots, including deep vein thrombosis and pulmonary embolism [R].
Carrying the variant does not mean that a blood clot is present or that one will inevitably occur. Many carriers never experience thrombosis. Its practical importance depends on personal and family history, age, pregnancy, estrogen exposure, surgery, immobility, body weight, smoking, other medical conditions, and additional genetic factors.
What is F2 rs1799963?
The F2 gene provides instructions for producing prothrombin, also known as coagulation factor II [R].
Prothrombin is made primarily in the liver and circulates in the bloodstream in an inactive form. When the coagulation system is activated, prothrombin is converted into thrombin. Thrombin then performs several important functions that support the formation and stabilization of a blood clot [R].
The variant is a well-established cause of prothrombin thrombophilia, also called:
prothrombin G20210A thrombophilia
F2-related thrombophilia
factor II thrombophilia
prothrombin gene mutation
prothrombin 20210 variant
It is considered a low-penetrance pathogenic risk variant. This means that it can meaningfully increase susceptibility while still being present in many people who never develop a blood clot.
How prothrombin normally supports blood clotting
Blood clotting is a tightly regulated process that prevents excessive bleeding after a blood vessel is damaged.
Prothrombin is one of the central proteins in this process [R]:
Tissue damage activates a series of coagulation factors.
Activated factor V and factor X help convert prothrombin into thrombin.
Thrombin converts soluble fibrinogen into fibrin.
Fibrin forms a mesh that strengthens and stabilizes the developing clot.
Thrombin also activates platelets and additional coagulation factors, amplifying the clotting response.
The body must produce enough thrombin to stop bleeding, but clotting activity must also remain controlled. Excessive or unnecessary thrombin generation can promote clots inside blood vessels where they obstruct normal circulation [R].
How rs1799963 changes prothrombin production
F2 rs1799963 does not create an abnormal prothrombin protein. Instead, it changes a regulatory region involved in processing the end of F2 messenger RNA [R].
The variant can make the RNA cleavage and polyadenylation process more efficient.
This may lead to [R]:
more stable or efficiently processed F2 messenger RNA
greater accumulation of F2 messenger RNA
increased prothrombin protein production
higher circulating prothrombin levels
increased potential for thrombin generation
This mechanism differs from Factor V Leiden. Factor V Leiden makes factor V harder to deactivate, while prothrombin G20210A primarily increases the amount of prothrombin available for conversion into thrombin.
What an F2 rs1799963 result can show
In forward-strand raw DNA notation, the possible rs1799963 results are:
Genotype | Result |
GG | The prothrombin G20210A variant was not detected. |
GA | One copy of the prothrombin G20210A variant was detected. |
AA | Two copies of the prothrombin G20210A variant were detected. |
One copy is called heterozygous prothrombin thrombophilia [R].
Two copies are called homozygous prothrombin thrombophilia [R].
Research generally associates one variant copy with an approximately two- to fivefold increase in relative venous thrombosis risk compared with people without the variant [R]. Two copies are rare and are believed to confer greater susceptibility, but the precise magnitude of that risk is difficult to establish because relatively few homozygous carriers have been studied [R].
These genotype meanings describe variant status. They do not provide an exact personal probability of developing a clot.
A GG result also does not rule out blood-clot risk. It only means that the prothrombin G20210A variant was not detected at rs1799963. Other inherited variants, acquired disorders, medications, medical conditions, and environmental exposures can still contribute to thrombosis.
Why the variant has several different names
F2 rs1799963 may appear under several naming systems:
rs1799963
prothrombin G20210A
20210G>A
F2 c.*97G>A
factor II G20210A
PT20210A
prothrombin gene mutation
These terms generally refer to the same variant. Some databases or raw DNA sources may use different strand orientations. A reverse-strand representation can display complementary letters, which is one reason allele orientation should be verified before interpreting a result. In the forward orientation used here, the common genotype letters are GG, GA, and AA.
Prothrombin thrombophilia and venous blood clots
The strongest association of F2 rs1799963 is with venous thromboembolism, commonly abbreviated as VTE [R].
Venous thromboembolism includes [R]:
deep vein thrombosis, or DVT
pulmonary embolism, or PE
Prothrombin thrombophilia may also contribute to clots in less common venous locations, including cerebral, portal, mesenteric, or hepatic veins. These unusual-site clots are much less common and usually involve several possible genetic, medical, or acquired risk factors.
Deep vein thrombosis
A deep vein thrombosis is a clot that develops in a deep vein, most often in the leg [R].
Possible symptoms include:
swelling in one leg or arm
unexplained pain or tenderness
warmth
redness or discoloration
pain that worsens while standing or walking
Some DVTs produce few or no noticeable symptoms.
Pulmonary embolism
A pulmonary embolism can occur when part of a venous clot breaks away, travels through the bloodstream, and blocks an artery in the lungs [R].
Possible warning signs include:
sudden shortness of breath
chest pain that may worsen with a deep breath
rapid or irregular heartbeat
coughing up blood
lightheadedness
fainting
Possible symptoms of pulmonary embolism require immediate medical assessment.
A genetic result cannot determine whether a person currently has a DVT or pulmonary embolism. Diagnosis requires clinical evaluation and appropriate testing or imaging.
Why the same genotype can have different meanings
F2 rs1799963 changes susceptibility rather than determining an outcome.
A person carrying one variant copy may never develop thrombosis. The same genotype may become more important when combined with other inherited or acquired factors.
Relevant factors can include:
a previous DVT or pulmonary embolism
a first-degree relative with venous thrombosis
increasing age
major surgery
serious injury
hospitalization
prolonged bed rest
a leg cast
long-distance travel
pregnancy
the postpartum period
estrogen-containing contraception
oral hormone replacement therapy
obesity
smoking
cancer
central venous catheters
antiphospholipid syndrome
another inherited thrombophilia
Clot risk can increase substantially when several factors are present at the same time. A genetic result should therefore be interpreted as one component of a broader clinical risk profile.
How common is prothrombin G20210A?
F2 rs1799963 is the second most common inherited thrombophilia variant after Factor V Leiden.
Its frequency varies substantially across ancestry groups and geographic populations [R].
The variant is found most often in people with European ancestry. Heterozygous carriage has been estimated at approximately 1.7% to 3% in general European and United States populations, with somewhat higher prevalence in parts of southern Europe [R]. It is much less common in many East Asian, African, and Indigenous American populations.
Why manual rs1799963 interpretation can be difficult
F2 rs1799963 is a relatively well-known marker, but manual interpretation can still create errors.
Potential problems include:
confusing F2 with F5 or Factor V Leiden
mistaking factor II thrombophilia for factor II deficiency
overlooking strand orientation
treating the historical and current variant names as separate findings
assuming a noncoding variant cannot have a functional effect
converting a relative-risk estimate into an exact personal probability
overlooking a missing result or no-call
interpreting the variant without considering Factor V Leiden
relying on weak or outdated sources
treating consumer genotyping as diagnostic testing
A raw DNA file may contain hundreds of thousands of markers. Proper interpretation requires locating the correct rsID, confirming orientation, evaluating evidence quality, identifying missing data, and placing the finding in appropriate context.
How GenesUnveiled analyzes F2 rs1799963
GenesUnveiled provides a structured way to analyze supported raw DNA files without manually researching each marker. The platform can check whether rs1799963 is present, match the recorded genotype to the expected forward-strand orientation, and organize the result within a consistent report system.
This helps reduce common interpretation problems involving:
manual searches through large raw DNA files
conflicting variant names
strand-orientation mistakes
missing markers and no-calls
unverified risk-allele directions
isolated interpretation without clear limitations
repeated research across multiple genetic databases
F2 is available through the free GeneExplorer, while prothrombin G20210A is also included among the High-Impact Variant Reports.
GenesUnveiled also organizes available findings across:
health-risk reports
High-Impact Variant Reports
gene activity
pharmacogenetics
nutrition and metabolism
traits
Smart Summary
SNP Lookup
The value is not simply revealing one publicly documented allele. It is automatically identifying and organizing the supported findings that are actually present in the user’s file while applying consistent strand, evidence, and missing-data logic.
Comments